TECEOS Trockenstechampullen

DRUG2 trials

Sponsors

Medical University Of Vienna

Conditions

Prostate Carcinomaprostate carcinoma

Phase 2

[177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with prostate cancer and biochemical but not radio-morphological local recurrence after primary therapy with curative intent: A Prospective Phase II Pilot Study

Not yet recruitingCTIS2024-519348-34-00

Medical University Of Viennaprostate carcinoma

Target: 26Updated: 2025-09-19

Neoadjuvant [177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with oligometastatic prostate cancer diagnosed using [68Ga]Ga-PSMA-11 PET imaging followed by radical prostatectomy: A Prospective Phase II Pilot Study

Not yet recruitingCTIS2024-519377-18-00

Medical University Of ViennaProstate Carcinoma

Target: 10Updated: 2025-11-17